185 related articles for article (PubMed ID: 3124289)
1. Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen).
Mirshahi M; Soria J; Soria C; Bertrand O; Mirshahi M; Basdevant A
Thromb Res; 1987 Nov; 48(3):279-89. PubMed ID: 3124289
[TBL] [Abstract][Full Text] [Related]
2. Resistance of gammaA/gamma' fibrin clots to fibrinolysis.
Falls LA; Farrell DH
J Biol Chem; 1997 May; 272(22):14251-6. PubMed ID: 9162058
[TBL] [Abstract][Full Text] [Related]
3. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
[TBL] [Abstract][Full Text] [Related]
4. Impact of fibrinogen carbamylation on fibrin clot formation and stability.
Binder V; Bergum B; Jaisson S; Gillery P; Scavenius C; Spriet E; Nyhaug AK; Roberts HM; Chapple ILC; Hellvard A; Delaleu N; Mydel P
Thromb Haemost; 2017 May; 117(5):899-910. PubMed ID: 28382370
[TBL] [Abstract][Full Text] [Related]
5. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Standeven KF; Ariëns RA; Whitaker P; Ashcroft AE; Weisel JW; Grant PJ
Diabetes; 2002 Jan; 51(1):189-97. PubMed ID: 11756340
[TBL] [Abstract][Full Text] [Related]
6. The binding sites on fibrin(ogen) for guinea pig liver transglutaminase are similar to those of blood coagulation factor XIII. Characterization of the binding of liver transglutaminase to fibrin.
Achyuthan KE; Mary A; Greenberg CS
J Biol Chem; 1988 Oct; 263(28):14296-301. PubMed ID: 2902081
[TBL] [Abstract][Full Text] [Related]
7. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
[TBL] [Abstract][Full Text] [Related]
9. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
Colick JA; Fisher LM
Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
[No Abstract] [Full Text] [Related]
10. ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function.
Liu CZ; Shih MH; Tsai PJ
Thromb Haemost; 2005 Aug; 94(2):286-94. PubMed ID: 16113817
[TBL] [Abstract][Full Text] [Related]
11. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
[TBL] [Abstract][Full Text] [Related]
12. Regulation of thrombin cleavage of plasma factor XIII bound to fibrin.
Greenberg CS; Achyuthan KE; Miraglia CC; Dobson JV
Ann N Y Acad Sci; 1986; 485():140-3. PubMed ID: 3471145
[No Abstract] [Full Text] [Related]
13. [Role of heparin in the process of blood coagulation and fibrinolysis].
Liapina LA
Usp Sovrem Biol; 1977; 84(3):338-52. PubMed ID: 343416
[No Abstract] [Full Text] [Related]
14. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
Gaule TG; Ajjan RA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203139
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the interactions of fibrinogen and soluble fibrin with washed rabbit platelets stimulated with ADP.
Harfenist EJ; Packham MA; Mustard JF
Thromb Haemost; 1985 Apr; 53(2):183-7. PubMed ID: 3927504
[TBL] [Abstract][Full Text] [Related]
16. Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII.
Mattheij NJ; Swieringa F; Mastenbroek TG; Berny-Lang MA; May F; Baaten CC; van der Meijden PE; Henskens YM; Beckers EA; Suylen DP; Nolte MW; Hackeng TM; McCarty OJ; Heemskerk JW; Cosemans JM
Haematologica; 2016 Apr; 101(4):427-36. PubMed ID: 26721892
[TBL] [Abstract][Full Text] [Related]
17. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanisms that regulate clot structure/function.
Ariëns RA
Thromb Res; 2016 May; 141 Suppl 2():S25-7. PubMed ID: 27207417
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
